Sabio Holdings, the Healthcare sector company, was revisited by a Wall Street analyst on May 1. Analyst Nicholas Cortellucci from Atrium Research maintained a Buy rating on the stock and has a C$0.50 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nicholas Cortellucci has given his Buy rating due to a combination of factors, despite Sabio’s Q4 and full-year results falling short of his expectations in a weak ad-tech environment. He highlights that, compared with the last non-election year, Sabio still delivered solid top-line growth, and he views current sector softness as cyclical rather than structural.
He also points to Sabio’s strengthening position in higher-potential areas such as programmatic offerings, international markets, and its Creator TV business, which management believes are gaining traction heading into 2026. In addition, the approaching election cycle is expected to revive political and advocacy advertising, supporting a recovery in revenue and profitability that underpins his maintained Buy rating, even as he revises the price target down to C$0.50 per share.
According to TipRanks, Cortellucci is ranked #10903 out of 12175 analysts.